固有免疫分子NLRP3炎性小体在慢性细菌性前列腺炎中的作用

摘要
图/表
参考文献(20)
相关文章 (1)

全文: PDF (439 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨固有免疫分子NOD样受体蛋白3（NLRP3）炎性小体在慢性细菌性前列腺炎（CBP）中的作用。方法选取2016年2月～2017年12月右江民族医学院附属医院（以下简称“我院”）泌尿外科收治的120例CBP患者为研究对象，同时选取我院同期进行体检的60名健康者为对照组。CBP患者采用三甲氧苄氨嘧啶配合磺胺甲恶唑治疗，持续12周。采用慢性前列腺炎症状评分量表、前列腺常规检查评估CBP患者治疗效果，酶联免疫吸附试验测定CBP患者NLRP3及其下游调控因子白细胞介素1β（IL-1β）和IL-18的表达。结果治疗前CBP患者NLRP3炎性小体含量显著高于对照组（P ＜ 0.001）；根据CBP患者NLRP3炎性小体含量的中位数为分界值，将患者分为高NLRP3组和低NLRP3组（每组各60例）。治疗后，低NLRP3组患者慢性前列腺炎症状评分（NIH-CPSI）量表疼痛、排尿、生存质量评分和总分值降低程度明显大于高NLRP3组（P ＜ 0.05），临床治疗有效率显著高于高NLRP3组（P ＜ 0.05）。治疗前，两组患者NLRP3、IL-1β和IL-18含量均显著高于对照组（P ＜ 0.05），治疗后，两组患者上述指标显著降低，而且低NLRP3组患者降低幅度明显大于高NLRP3组（P ＜ 0.05）。治疗后两组患者前列腺液白细胞和卵磷脂小体计数比较，差异无统计学意义（P ＞ 0.05），且两组受试对象在治疗过程中均未出现严重的不良反应。结论 NLRP3炎性小体含量改变是影响CBP治疗效果的潜在因素，靶向调控NLRP3炎性小体水平有助于提高CBP的临床疗效。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	何涛1 黄华武1 曾永龙2 郭子维2 谢秋语2

关键词 ：慢性细菌性前列腺炎, NOD样受体蛋白3, 炎性小体

Abstract：Objective To investigate the role of the innate immune molecule NLRP3 inflammasome in chronic bacterial prostatitis (CBP). Methods The 120 cases of CBP patients who admitted to Department of Urology, Affiliated Hospital of Youjiang Medical College (hereinafter referred to as "our hospital") for Nationalities were selected as the research objects from February 2016 to December 2017. The 60 healthy subjects in the same period in our hospital were selected as the control group. CBP patients were treated with trimethoprim plus sulfamethoxazole for 12 weeks. The chronic prostatitis symptom score scale (NIH-CPSI) and routine prostate test were used to evaluate the therapeutic effects of CBP patients. The expression of NLRP3 and its downstream regulatory elements interleukin 1β (IL-1β) and IL-18 were measured by enzyme linked immunosorbent assay in CBP patients. Results Before treatment, the content of NLRP3 inflammatory corpuscule in CBP patients was significantly higher than that in the control group (P ＜ 0.001). Patients were divided into high NLRP3 group and low NLRP3 group (60 cases in each group) according to the median NLRP3 inflammatory body content in CBP patients as the cut-off value. After treatment, pain, urination, quality of life scores and total scores of NIH-CPSI in low NLRP3 group were significantly superior than those in high NLRP3 group (P ＜ 0.05). The clinical response rate of low NLRP3 group was higher than that of high NLRP3 group (P ＜ 0.05). Before treatment, the levels of NLRP3, IL-1β and IL-18 in both groups were significantly higher than those in healthy subjects (P ＜ 0.05). After treatment, the above indexes were significantly decreased in both groups, and the reduction in low NLRP3 group were significantly greater than high NLRP3 group (P ＜ 0.05). After treatment, there was no significant difference in leukocyte and lecithin counts between the two groups (P > 0.05), and no significant adverse reactions were observed in both groups during the treatment. Conclusion The change of NLRP3 inflammasome content is a potential factor that affects the therapeutic effect of CBP. Targeting the NLRP3 inflammasome level can improve the clinical efficacy of CBP.

Key words： Chronic bacterial prostatitis Nod-like receptor protein 3 Inflammasome

基金资助:广西高校中青年教师基础能力提升项目（2018K Y0436）；
右江民族医学院校级科研项目和广西高校重点实验室开放项目（yy2016ky001）。

通讯作者: 黄华武（1966.6-），男，主任医师；研究方向：前列腺疾病、泌尿系结石、泌尿系肿瘤的诊断和治疗。

作者简介: 何涛（1980.10-），女，硕士；研究方向：临床免疫学检验。

引用本文:

何涛1 黄华武1 曾永龙2 郭子维2 谢秋语2. 固有免疫分子NLRP3炎性小体在慢性细菌性前列腺炎中的作用[J]. 中国医药导报, 2019, 16(10): 157-161.
HE Tao1 HUANG Huawu1 ZENG Yonglong2 GUO Ziwei2 XIE Qiuyu2. Role of the innate immune molecule NLRP3 inflammasome in chronic bacterial prostatitis. 中国医药导报, 2019, 16(10): 157-161.

链接本文:

http://www.yiyaodaobao.com.cn/CN/ 或 http://www.yiyaodaobao.com.cn/CN/Y2019/V16/I10/157

[1] Rees J，Abrahams M，Doble A，et al. Diagnosis and treatment of chronic bacterial prostatitis and chronic prostatitis/chronic pelvic pain syndrome：a consensus guideline [J]. BJU Int，2015，116（4）：509-525.
[2] Murphy SF，Schaeffer AJ，Done JD，et al. Commensal bacterial modulation of the host immune response to ameliorate pain in a murine model of chronic prostatitis [J]. Pain，2017，158（8）：1517-1527.
[3] Coll RC，Robertson AAB，Chae JJ，et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases [J]. Nature Medicine，2015，21（3）：248.
[4] Jo EK，Kim JK，Shin DM，et al. Molecular mechanisms regulating NLRP3 inflammasome activation [J]. Cell Mol Immunol，2016，13（2）：148.
[5] Zhou Q，Zhang L，Feng C. Wogonoside ameliorates carrageenan-induced chronic nonbacterial prostatitis in rats [J]. Int J Clin Exp Med，2017，10（12）：16203-16209.
[6] 那彦群，叶章群，孙光.2011版中国泌尿外科疾病诊断治疗指南[M].北京：人民卫生出版社，2011.
[7] Gao J，Zhang X. PS-08-007 Relationships between intravaginal ejaculatory latency time and national institutes of health-chronic prostatitis symptom index in the four types of premature ejaculation syndromes：A large observational study in China [J]. J Sex Med，2017，14（4）：e133.
[8] Wagenlehner FME，van Till JWO，Houbiers JGA，et al. Fatty acid amide hydrolase inhibitor treatment in men with chronic prostatitis/chronic pelvic pain syndrome：an adaptive double-blind，randomized controlled trial [J]. Urology，2017，103：191-197.
[9] Xie Q，Shen WW，Zhong J，et al. Lipopolysaccharide/adenosine triphosphate induces IL-1β and IL-18 secretion through the NLRP3 inflammasome in RAW264. 7 murine macrophage cells [J]. Int J Mol Med，2014，34（1）：341-349.
[10] Misawa T，Takahama M，Kozaki T，et al. Microtubule-driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasome [J]. Nat Immunol，2013，14（5）：454-460.
[11] Heneka MT，Kummer MP，Stutz A，et al. NLRP3 is activated in Alzheimer/'s disease and contributes to pathology in APP/PS1 mice [J]. Nature，2013，493（7434）：674-678.
[12] Haneklaus M，O’Neill LAJ，Coll RC. Modulatory mechanisms controlling the NLRP3 inflammasome in inflammation：recent developments [J]. Curr Opin Immunol，2013， 25（1）：40-45.
[13] Perletti G，Marras E，Wagenlehner FM，et al. Antimicrobial therapy for chronic bacterial prostatitis [J]. Cochrane Database Syst Rev，2013，8（12）：CD009071.
[14] Boehm BJ，Colopy SA，Jerde TJ，et al. Acute bacterial inflammation of the mouse prostate [J]. The Prostate，2012， 72（3）：307-317.
[15] Hughes MM，O′Neill L. Metabolic regulation of NLRP3 [J]. Immunological Reviews，2018，281（1）：88-98.
[16] Christ A，Günther P，Mar L，et al. Western diet triggers NLRP3-dependent innate immune reprogramming [J]. Cell，2018，172（1-2）：162.
[17] Li Y，Pan Y，Gao L，et al. Naringenin protects against acute pancreatitis in two experimental models in mice by NLRP3 and Nrf2/HO-1 pathways [J]. Mediators Inflamm，2018，2018（3）：1-13.
[18] Jr CL，Maile R，Jones SW，et al. HMGB1/IL-1β complexes in plasma microvesicles modulate immune responses to burn injury [J]. PLoS One，2018，13（3）：e0 195 335.
[19] Wada T，Toma T，Miyazawa H，et al. Longitudinal analysis of serum interleukin-18 in patients with familial Mediterranean fever carrying MEFV mutations in exon 10 [J]. Cytokine，2018，104：143-146.
[20] Hahn AM，Myers JD，McFarland EK，et al. Interleukin-driven insulin-like growth factor promotes prostatic inflammatory hyperplasia [J]. J Pharmacol Exp Ther，2014， 351（3）：605-615.